Yunhu Tech Secures Tens of Millions in Pre-A Funding to Expand Business Infrastructure, Product Portfolio, and Distribution Channels
According to VCBeat, on December 5, Yunhu Technology, China’s leading third-party primary care medical testing service platform, announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was led by Yuanjing Capital, with Morningside Venture Capital participating as a co-investor. Chen Xiaobing, founder of Yunhu Technology, stated that the funds raised will be primarily used to build out its business framework, enhance its product portfolio, and further expand its sales channels.
Currently, the overall size of China's medical laboratory testing market exceeds RMB 200 billion, with third-party independent laboratories accounting for only 4% of the market share. The lower-tier distribution channels are highly fragmented, indicating substantial market potential and an urgent need for consolidation. Meanwhile, since 2015, the Chinese government has been promoting the establishment of a tiered diagnosis and treatment system, explicitly calling for enhanced healthcare service capabilities at the grassroots level in both urban and rural areas, while encouraging the outsourcing of clinical laboratory services.
Leveraging the golden era of healthcare reform-driven tiered diagnosis and treatment systems and the booming health services industry, Yunhu Technology has begun to strategically position itself in the third-party medical laboratory testing market. It provides outsourced medical testing services to private clinics and Tier 4 and 5 hospitals, enabling primary healthcare institutions to offer medical testing items while also delivering specialized cold-chain logistics services. This section outlines the positioning, functions, advantages, and interrelationships among its three core platforms: “Yunhu Easy Test,” “Yunhu Cold Chain,” and “Yunhu Guardian.”
“Yunhu Yijian” Platform is built on the vision of “making medical testing simpler and diagnosis more convenient,” striving to create China’s first Internet-plus platform for integrating resources in the medical testing industry. By leveraging efficient platform resource integration capabilities and convenient payment solutions, it aims to transform healthcare-seeking habits among the Chinese population and achieve rapid convergence of traffic (data), talent, and capital. The platform provides customers with convenient, cost-effective laboratory testing services, health management services, and value-added services, while ensuring that test results are secure, reliable, and fully visible, controllable, and traceable throughout the entire process.
“Yunhu Cold Chain” is a platform dedicated to providing enterprises with secure and comprehensive nationwide cold-chain logistics services for pharmaceuticals, samples, and biological reagents. It also provides offline medical cold-chain logistics support for the “Yunhu Yijian” platform. Committed to delivering high-quality, one-stop nationwide cold-chain services to life science enterprises, “Yunhu Cold Chain” aims to establish a nationwide platform-based logistics system for the life sciences and medical sectors, and to become China’s leading internet-plus medical testing cold-chain logistics brand in the life sciences industry.
“Cloud Call Guardian” Platform, as an integrated platform for the consolidation, promotion, and service of medical resources, employs professional and secure blood testing technologies to provide users with precise medical diagnostic services. By integrating resources from professional physicians and nurses, it offers a convenient service platform for marketing, sales, testing, and management to various medical testing institutions and healthcare professionals. Together with “Cloud Call Easy Test” and “Cloud Call Cold Chain,” the two other platforms developed by our company, “Cloud Call Guardian” enables online-offline information connectivity, delivering convenient and cost-effective mobile health services to users.
Through Yunhu Technology’s self-built cold-chain logistics system, test samples are delivered to the laboratory at maximum speed. After testing, analysis, and review, the results are uploaded to the Yunhu Laboratory Services Cloud Platform, where clients can log in to download and view them. The platform also provides precise laboratory services—including interpretation of test reports and recommendations for disease diagnosis and treatment—as well as health management and value-added services, helping to enhance the comprehensive diagnostic and therapeutic capabilities of primary healthcare institutions.
Tests have shown that conducting medical laboratory testing via the Cloud Call Platform reduces the turnaround time by at least half compared to traditional channels, while also lowering testing costs by 20%. Currently, the Cloud Call Platform has integrated more than 400 medical laboratory institutions, including KingMed Diagnostics, Adicon, and Boao, along with hundreds of upstream suppliers and partners. It also connects with over a thousand healthcare institutions in Beijing, Zhejiang, Fujian, Henan, Hunan, Jiangxi, Jiangsu, and other regions, having cumulatively served hundreds of thousands of patients.
In addition to routine testing, the Yunhu Platform offers more than 2,000 test items ranging from basic to advanced levels, including biochemistry, chemiluminescent immunoassays, and genetic diagnostics. Chen Xiaobin stated that the Yunhu Platform remains committed to bringing diagnostic products to grassroots healthcare institutions, empowering them with medical laboratory capabilities. Meanwhile, it reduces redundant logistics costs and marketing expenses for various medical laboratories, enabling them to focus on the research, development, and production of diagnostic products.
Meanwhile, Yunhu Technology launched the “Mi Gene” genetic testing service platform this year. Users can place orders directly via WeChat Official Accounts, mobile apps, and other channels. The platform provides a comprehensive suite of services, including free on-site blood collection and sampling, sample delivery for testing, report interpretation, and health recommendations.
This is partly attributable to Yunhu’s team, which boasts a technical service group with long-term expertise in the medical testing industry and a professional R&D team dedicated to internet platform development. Meanwhile, Yunhu Technology has independently established a cold-chain logistics system as a third-party provider, enhancing transportation efficiency, reducing costs, and addressing key constraints on the growth of third-party medical testing services.
“By promoting the ‘Internet + Healthcare’ service model, Yunhu Technology has built an internet platform that enables information sharing among the public, medical institutions at all levels, and third-party medical testing laboratories, thereby helping ordinary people enjoy equitable access to high-quality medical services.” Chen Xiaobin believes that in the field of medicine, prevention is far more important than treatment. Promoting the widespread adoption of genetic testing can enable more people to understand and utilize it for disease prevention.
Tian Min, Partner at Yuanjing Capital, the lead investor in this round, stated, “Yunhu Technology connects medical laboratories with primary healthcare institutions through its specialized service capabilities, systematically reducing the costs for medical laboratories to extend their services to the grassroots level and further stimulating vitality in the medical testing market.” Tian Min noted that the Yunhu team comprises professionals from leading enterprises in the clinical diagnostics and genomics sectors, possessing an in-depth understanding of the pain points in primary healthcare. With the relaxation of national policies regarding grassroots clinics, Yunhu is well-positioned to leverage its years of market expertise to support tiered diagnosis and treatment, empowering grassroots clinics to enhance their diagnostic testing capabilities and diversify their product offerings.